Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > ORGANIZATION
ORGANIZATION
- Kazuhiko Ezawa to Become Chuikyo JMA Rep after Matsumoto
October 28, 2021
- JGA Sets Out 5-Pronged Measures to Restore Trust in Generics
October 27, 2021
- Kenporen’s Masato Matsumoto to Take Over from Kono as Chuikyo Payer Rep
October 27, 2021
- Main Focus of INES Proposal Is Securing Resources to Reward Innovation, Not Macroeconomic Indexing
October 25, 2021
- Choseido Suspended from JGA for 5 Years after Biz Suspension Order
October 15, 2021
- EFPIA to Ponder Position on Macroeconomic Indexing with Patient Access as Top Priority, Continue Dialogue with Japan Govt
October 14, 2021
- Plaintiffs, Lawyers Renew Opposition to Restart of HPV Vaccine Recommendation
October 13, 2021
- JGA Vows Strict Response to Choseido’s Biz Suspension Order
October 12, 2021
- IFPW Chair Vows to Boost Reliability of Healthcare Supply Chain as Tokyo Confab Ends
October 8, 2021
- INES’ Patient-Centered Policy Initiative Going Full Throttle, Proposal Eyed before 2022 Honebuto Paper
October 7, 2021
- JMA Exec Chides Pharma for Requesting Price Measure to Ensure Stable Supplies, Says Compliance System Should Come First
October 7, 2021
- Biocommunity for Greater Tokyo Area Boots Up, Aims to Form Bioinnovation Hub
October 7, 2021
- Amy Jackson to Leave PhRMA Japan, Kawabata to Take Up Interim Role
October 6, 2021
- 1,749 Generic Products Now under Supply Restrictions: JGA
October 5, 2021
- Think Twice before Issuing Long-Term Prescriptions for Supply-Curbed Generics: JMA
October 5, 2021
- MEJ Study Group Calls for Electronic Medical Chart Reform to Expedite Clinical Trials, New Drug Development
October 4, 2021
- FPMAJ to Define Shipment Situation in Preparation for Supply Information Centralization
October 1, 2021
- FPMAJ Chief Praises Political Acumen of New LDP Leader Kishida, Seeks Support for Industry
September 30, 2021
- Generic Use Rate Slips to 79.8% in April-June: JGA
September 30, 2021
- Chuikyo Payer Rep Wants to Cut into Cost-Based Method, Adjustment Rate, Off-Year Revision in FY2022 Reform, Eyes Special Rules for Aducanumab
September 27, 2021
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…